[go: up one dir, main page]

WO2004110349A3 - Sars t cell epitopes and methods for identifying same - Google Patents

Sars t cell epitopes and methods for identifying same Download PDF

Info

Publication number
WO2004110349A3
WO2004110349A3 PCT/US2004/015026 US2004015026W WO2004110349A3 WO 2004110349 A3 WO2004110349 A3 WO 2004110349A3 US 2004015026 W US2004015026 W US 2004015026W WO 2004110349 A3 WO2004110349 A3 WO 2004110349A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
epitopes
methods
cell epitopes
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/015026
Other languages
French (fr)
Other versions
WO2004110349A2 (en
Inventor
Morten Nielsen
Ole Lund
Claus Lundegaard
Peder Worning
Soren Buus
Soren Brunak
Sune Justesen
Christina Sylvester-Hvid
Gustav A Roder
Kasper Lamberth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Priority to CA002525778A priority Critical patent/CA2525778A1/en
Publication of WO2004110349A2 publication Critical patent/WO2004110349A2/en
Priority to IL171924A priority patent/IL171924A0/en
Anticipated expiration legal-status Critical
Publication of WO2004110349A3 publication Critical patent/WO2004110349A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

In a first aspect the present invention consists of T cell epitopes in the Severe Acute Respiratory Syndrome (SARS) virus genome. More specifically there is provided 180 class I linear peptide epitopes and 200 class II linear epitopes from the SARS Virus genome. In a second aspect the invention also consists of variants of these sequences. In a third aspect this invention consists of a method to predict these sequences from genome data and to validate the predications experimentally. In a fourth aspect the present invention provides compositions including these epitopes for use in a vaccine and to induce a T cell response in a subject, or as a diagnostic tool.
PCT/US2004/015026 2003-05-14 2004-05-14 Sars t cell epitopes and methods for identifying same Ceased WO2004110349A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002525778A CA2525778A1 (en) 2003-05-14 2004-05-14 T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same
IL171924A IL171924A0 (en) 2003-05-14 2005-11-13 T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300725 2003-05-14
DKPA200300725 2003-05-14

Publications (2)

Publication Number Publication Date
WO2004110349A2 WO2004110349A2 (en) 2004-12-23
WO2004110349A3 true WO2004110349A3 (en) 2006-03-23

Family

ID=33547529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015026 Ceased WO2004110349A2 (en) 2003-05-14 2004-05-14 Sars t cell epitopes and methods for identifying same

Country Status (3)

Country Link
CA (1) CA2525778A1 (en)
IL (1) IL171924A0 (en)
WO (1) WO2004110349A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2215108A4 (en) * 2007-10-23 2012-07-04 Univ Colorado COMPETITIVE INHIBITORS OF EXPRESSION OF INVARIANT CHAINS AND / OR BINDING OF AN ECTOPIC CLIP
EP2360173B1 (en) * 2008-11-28 2016-01-13 NOF Corporation Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
WO2018102317A1 (en) * 2016-11-29 2018-06-07 The Regents Of The University Of California Modulation of p53 for the treatment of cancer
EP3892297A1 (en) * 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)
CN111440229B (en) * 2020-04-13 2021-08-03 中国人民解放军军事科学院军事医学研究院 Novel coronavirus T cell epitopes and their applications
EP4138907A4 (en) * 2020-04-20 2024-08-21 The General Hospital Corporation HIGHLY CROSS-LINKED CORONAVIRUS IMMUNOGEN COMPOSITION
CA3176320A1 (en) * 2020-04-20 2021-10-28 Richard STRATFORD Sars-cov-2 vaccines
WO2021228853A1 (en) * 2020-05-11 2021-11-18 Ose Immunotherapeutics Vaccine against sars-cov virus
WO2021256795A1 (en) * 2020-06-15 2021-12-23 한국과학기술원 Epitope of new coronavirus and use thereof
AU2021293931A1 (en) * 2020-06-17 2023-01-19 Ahs Hospital Corp. SARS-CoV-2 immunodominant peptides and uses thereof
WO2022026921A1 (en) * 2020-07-30 2022-02-03 Repertoire Immune Medicines, Inc. Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
WO2022067062A1 (en) * 2020-09-24 2022-03-31 Epivax, Inc. Rapid development of prophylactic broad spectrum vaccine for sars-cov-2 using phage mediated antigen delivery system
JP2023550094A (en) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Constructs of SARS-COV-2 immunodominant peptides and uses thereof
CN112876542B (en) * 2021-02-08 2021-10-29 暨南大学 A novel coronavirus T cell antigen epitope peptide and its application
WO2022178216A2 (en) * 2021-02-22 2022-08-25 Cotropia Joseph Corona virus antigens and epitopes and proteins that bind thereto
US20240181070A1 (en) * 2021-04-08 2024-06-06 Ramot At Tel-Aviv University Ltd. Nanovaccines for treatment of viral diseases
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
CN113666989B (en) * 2021-08-12 2023-08-29 中国科学技术大学 Novel coronavirus CD8+ T cell epitope peptide and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] "putative orflab polyprotein (SARS coronavirus)", accession no. NCBI Database accession no. (NP828849) *
XU Z ET AL: "The R Protein of SARS-CoV: Analyses of Structure and Function Based on Four Copmlete Genome Sequences of Isolates BJ101-BJ104.", GENOMICS PROTEOMICS BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05-01), pages 155 - 165, XP001182393 *

Also Published As

Publication number Publication date
CA2525778A1 (en) 2004-12-23
IL171924A0 (en) 2006-04-10
WO2004110349A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2004110349A3 (en) Sars t cell epitopes and methods for identifying same
WO2004074455A3 (en) Fc REGION VARIANTS
DE602004024542D1 (en) SUB-VACCINE AGAINST THE RESPIRATORY SYNZYTIALVIRUS
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
WO2005111212A3 (en) Biological bar code
IL164966A0 (en) 3?-Ä2Z)-Ä1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylideneÜhydrazinoÜ-2'-hydroxy-Ä1,1'-biphenylÜ-3-carboxylic acid bis-(monoethanolamine)
DE50208862D1 (en) GAS TURBO GROUP
NZ543467A (en) The severe acute respiratory syndrome coronavirus
UA84284C2 (en) Methods for treating, preventing and detecting helicobacter infection
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
BRPI0410467A (en) compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
DK1399590T3 (en) Happier mapping
DE50209684D1 (en) GAS TURBO GROUP
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
NO20044398L (en) Photocatalysts containing titanium oxide, as well as the process and use thereof
WO2005051313A3 (en) Methods and reagents for treating, preventing and diagnosing bunyavirus infection
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2005035794A3 (en) Detection of prrsv
WO2004091524A3 (en) Respiratory virus vaccines
ATE542810T1 (en) METHOD FOR PRODUCING 3,5-DI-OMIKRON-ACYL-2-FLUORINE-2-C-METHYL-D-RIBONO GAMMA-LACTONE
WO2004029835A3 (en) System and method for associating different types of media content
WO2005037855A3 (en) T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
WO2007120120A3 (en) Attenuated human parainfluenza virus, methods and uses thereof
DE60224280D1 (en) USE OF OXYTOCIN FRAGMENTS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR EFFECTIVENESS OF EUSTASIS
NO20052680D0 (en) Improvement agent containing fuel.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171924

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2525778

Country of ref document: CA

122 Ep: pct application non-entry in european phase